Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease

July 2017

Xadago (ZAH-dah-goh) will be a new add-on for Parkinson's disease.

Think of Xadago (safinamide) as similar to selegiline (Eldepryl, etc) or rasagiline (Azilect, etc).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote